Social Media is all a buzz right now and everyone from industry giants, mom and pop shops, non-profit community organizations, and even the U.S government are trying to figure out how to use it to their advantage. Some organizations find social media platforms wildly successful, while others can’t quite hit their mark. Just days before Facebook opened on NASDAQ, General Motors Co. decided to stop their advertising on Facebook. Were their ads ineffective, or was GM not correctly seeing the potential power of the social network to build brand loyalty? Should we care?
For many organizations that are looking for quick short-term returns on their investment dollars in the pay-per-click advertising might be disappointed with the results. As the article points out, the value of the social media user is that they become an advocate of the brand. Many are wondering if this is a sign of things to come for the advertising in the Facebook social media world; since it remains to be seen whether this virtual user engagement correlates with a return on investment (ROI). Is it possible to accurately define or measure ROI in social media?
One of the great powers of social media is creating a community and buzz through social connectedness—a virtual word of mouth system. Your social reach is indicative of a classic Wayne’s World 2 scene, “You know how these things start… one guy tells another guy something, then he tells two friends, and they tell two friends, and they tell their friends, and so on”. If you witness a friend “like” a page or event, they are giving their social network a thumbs-up that they interested in a particular company, product, event, etc.—hey, and you might too. Conceivably your “friends” are more likely to share similar interests…or least be curious enough to check it out.
But how can this be applied to academic and clinical research realm—and should it? By creating a community around a specific disease or research area, you can create a group who has common interests and build loyalty within that group—that is if you can foster trust among your group members as a credible, reliable and useful resource. For instance, if you are a group member or follower of a specific group related to diabetes treatments and you see a fellow member of that group “likes” a diabetes clinical trial, then you might be more inclined to also check out that clinical trial.
The use of social media in clinical trial recruitment is a tricky area that still is trying to find guidance. In recent blog post by Rebar Interactive, brings this issue to light and raises A Social Media Question IRBs Must Ask about how to appropriately use the power of social media to raise awareness of clinical trial opportunities; all the while, being mindful of patient privacy. This can be counterproductive in a virtual environment and age where absolute privacy may be disintegrating, with each allow access button we click.
The FDA still has not released official regulation on what is/isn’t allowed in recruitment via social media mediums. As a result, social media for clinical trial recruitment is such a gray area which is constantly evolving in its application. Although times are changing, IRBs shy away from encouraging the use of social media in patient recruitment because of the uncertainty in how to regulate it. In the meantime, you don’t want to be left outside the social circle, so here is a helpful resource to help navigate the unregulated waters: Patient Recruitment, Regulatory & IRB Considerations for Social Media
BioMed 2.0 